| Literature DB >> 32518714 |
Shuren Guo1, Xiaohuan Mao2, Yunmeng Yan1, Yan Zhang1, Liang Ming1.
Abstract
BACKGROUND: Oxidative-stress (OS) was causal in the development of cell dysfunction and insulin resistance. Streptozotocin (STZ) was an alkylation agent that increased reactive oxygen species (ROS) levels. Here we aimed to explore the oxidative-stress and related RNAs in the liver of STZ-induced diabetic mice.Entities:
Keywords: Differentially expressed RNAs; Liver; Metabolism; Oxidative-stress; STZ
Year: 2020 PMID: 32518714 PMCID: PMC7261117 DOI: 10.7717/peerj.8983
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Biochemical parameters in control mice and STZ-induced diabetic mice over 4 weeks.
(A) Plasma concentration of fasting blood glucose. (B) Body weight.
Distribution of various biochemical parameters of control (n = 10) and diabetic groups (n = 17) four weeks after STZ injection (x ± s).
| Groups | Diabetic groups | Normal groups | |
|---|---|---|---|
| Weight (kg) | 18.02 ± 3.86 | 20.4 ± 3.28 | <0.001 |
| Fast Blood Glucose (mmol/L) | 24.02 ± 4.35 | 5.4 ± 0.82 | <0.001 |
| Fast Insulin level (mIU/L) | 13.45 ± 8.25 | 31.45 ± 3.32 | <0.001 |
| MDA (nmol/L) | 1.90 ± 0.78 | 0.90 ± 0.28 | <0.001 |
| Total SOD (U/ml) | 0.80 ± 0.3 | 1.10 ± 0.2 | <0.001 |
| Cytochrome c((pmol/L) | 3.2 ± 0.58 | 1.70 ± 0.6 | 0.004 |
| 8-iso-PGF2 | 2.57 ± 0.83 | 1.23 ± 0.48 | <0.001 |
Figure 2Characteristic of RNA-sequence data.
(A) Venn diagram of Novel lncRNAs identified by 4 methods, (B) Differentially expressed lncRNAs, (C) Variation statistics, (D) Alternative splice statistics, SKIP, Skipped Exon; SKIP, Multi-exon SKIP; IR, Intron Retention; MIR, Multi-IR; AE, Alternative Exon Ends; TSS, Transcription Start Site; TTS, Transcription Terminal Site; XSKIP, Approximate SKIP; XMSKIP, Multi-exon SKIP; XIR, Approximate IR; XMIR, Approximate MIR; XAE, Approximate AE.
Figure 3Representation Go terms of differentially expressed genes in the STZ-induced DM mice liver. The vertical ordinate represents Go term, the horizontal ordinate represents sample name. The different color represents the enrichment degree.
(A) Biological process enrichment of dysregulated lncRNAs. (B) Molecular function enrichment of dysregulated lncRNAs.
Figure 4Representation pathway terms of differentially expressed genes in the STZ-induced DM mice liver.
The vertical ordinate represents the KEGG Go term, the horizontal ordinate represents sample name. The different color represents the enrichment degree.
Effects of STZ on hepatic gene expression.
| KEGG pathway/Gene | Gene name | Type | Fold change | |
|---|---|---|---|---|
| Toll-like receptor signaling pathway | ||||
| ENSMUSG00000025498| | Irf7 | Interferon regulatory factor 7 | mRNA | 2.58 |
| ENSMUSG00000085667| | Gm12992 | PREDICTED: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform isoform X2 [Mus musculus] | processed_transcript | 2.03 |
| ENSMUSG00000021250| | FOS | Proto-oncogene protein c-fos | mRNA | 0.54 |
| ENSMUSG00000027398| | IL1B | Interleukin 1 beta | mRNA | 0.48 |
| ENSMUSG00000051439| | CD14 | Monocyte differentiation antigen | mRNA | 0.49 |
| ENSMUSG00000020901| | PIK3R1_2_3 | Phosphoinositide-3-kinase regulatory subunit alpha/beta/delta | mRNA | 2.19 |
| ENSMUSG00000028111| | CTSK | Cathepsin K | 0.46 | |
| ENSMUSG00000112163| | MAP3K7, TAK1 | Processed_pseudogene | Processed_pseudogene | 0.16 |
| Epstein-Barr virus infection | ||||
| ENSMUSG00000085995| | Gm2788 | Predicted gene 2788 | ncRNA | 2.57 |
| ENSMUSG00000105987| | AI506816 | Expressed sequence AI506816 | ncRNA | 2.37 |
| ENSMUSG00000004951| | Hspb1 | Heat shock protein 1 | mRNA | 2.01 |
| ENSMUSG00000019942| | Cdk1 | Cyclin-dependent kinase 1 | mRNA | 3.04 |
| ENSMUSG00000073406| | H2-Bl | Histocompatibility 2 | mRNA | 4.29 |
| ENSMUSG00000085667| | Gm12992 | Predicted gene 12992 | ncRNA | 2.64 |
| ENSMUSG00000112879| | AC158802.2 | Processed_pseudogene | 4.41 | |
| ENSMUSG00000030724| | Cd19 | CD19 antigen | mRNA | 2.25 |
| ENSMUSG00000038086| | Hspb2 | Heat shock protein 2 | mRNA | 5.11 |
| ENSMUSG00000113137| | AC157515.2 | Processed_pseudogene | 5.39 | |
| ENSMUSG00000078915| | Hsp25-ps1 | Heat shock protein beta-1 | mRNA | 2.15 |
| ENSMUSG00000020901| | Pik3r5 | Phosphoinositide-3-kinase regulatory subunit 5 | mRNA | 0.41 |
| ENSMUSG00000079507| | H2-Q1 | Histocompatibility 2, Q region locus 1 | mRNA | 0.48 |
| ENSMUSG00000112163| | AC158606.2 | Processed_pseudogene | 0.25 | |
| ENSMUSG00000092243| | Gm7030 | Predicted gene 7030 | ncRNA | 0.18 |
| ENSMUSG00000073405| | H2-T-ps | Unprocessed_pseudogene | 0.47 | |
| ENSMUSG00000075042| | 4930431P03Rik | RIKEN cDNA 4930431P03 gene | Processed_transcript | 0.09 |
| Hepatitis B | ||||
| ENSMUSG00000025498| | Irf7 | Interferon regulatory factor 7 | mRNA | 2.58 |
| ENSMUSG00000070348| | Ccnd1 | Cyclin D1 | mRNA | 2.74 |
| ENSMUSG00000018983| | E2f2 | E2F transcription factor 2 | mRNA | 2.09 |
| ENSMUSG00000081158| | Gm13521 | Processed_pseudogene | 7.02 | |
| ENSMUSG00000097327| | E030030I06Rik | RIKEN cDNA E030030I06 gene | mRNA | 2.43 |
| ENSMUSG00000081121| | Gm12791 | Processed_pseudogene | 8.38 | |
| ENSMUSG00000085667| | Gm12992 | Predicted gene 12992 | ncRNA | 2.64 |
| ENSMUSG00000021250| | Fos | FBJ osteosarcoma oncogene | mRNA | 0.23 |
| ENSMUSG00000020901| | Pik3r5 | Phosphoinositide-3-kinase regulatory subunit 5 | mRNA | 0.41 |
| Apoptosis | ||||
| ENSMUSG00000085667| | Gm12992 | Predicted gene 12992 | ncRNA | 2.64 |
| ENSMUSG00000026072| | Il1r1 | Interleukin 1 receptor, type I | mRNA | 0.50 |
| ENSMUSG00000027398| | Il1b | Interleukin 1 beta | mRNA | 0.31 |
| ENSMUSG00000020901| | Pik3r5 | Phosphoinositide-3-kinase regulatory subunit 5 | mRNA | 0.41 |
| ENSMUSG00000002997| | Prkar2b | Protein kinase, cAMP dependent regulatory, type II beta | mRNA | 0.48 |
| Protein processing in endoplasmic reticulum | ||||
| ENSMUSG00000057789| | Bak1 | BCL2-antagonist/killer 1 | mRNA | 2.12 |
| ENSMUSG00000083261| | Gm7816 | Processed_pseudogene | 2.10 | |
| ENSMUSG00000007033| | Hspa1l | Heat shock protein 1-like | mRNA | 2.55 |
| ENSMUSG00000100615| | Gm5511 | Processed_pseudogene | 7.36 | |
| ENSMUSG00000009092| | Derl3 | Der1-like domain family, member 3 | mRNA | 0.42 |
| ENSMUSG00000090197| | Dnaja1-ps | Processed_pseudogene | 0.22 | |
| Peroxisome | ||||
| ENSMUSG00000031278| | Acsl4 | acyl-CoA synthetase long-chain family member 4 | mRNA | 2.90 |
| ENSMUSG00000020333| | Acsl6 | acyl-CoA synthetase long-chain family member 6 | mRNA | 3.57 |
| ENSMUSG00000007908| | Hmgcll1 | 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase-like 1 | mRNA | 2.12 |
| ENSMUSG00000055782| | Abcd2 | ATP-binding cassette, sub-family D (ALD), member 2 | mRNA | 0.09 |
| ENSMUSG00000027870| | Hao2 | Hydroxyacid oxidase 2 | mRNA | 0.02 |
| ENSMUSG00000021416| | Eci3 | Enoyl-Coenzyme A delta isomerase 3 | mRNA | 0.27 |
| ENSMUSG00000027674| | Pex5l | Peroxisomal biogenesis factor 5-like | mRNA | 0.15 |
| ENSMUSG00000063428| | Ddo | D-aspartate oxidase, isoform CRA_a, partial [Mus musculus] | mRNA | 2.35 |
| ENSMUSG00000026272| | Agxt | Serine–pyruvate aminotransferase, mitochondrial isoform 1 precursor [Mus musculus] | mRNA | 0.45 |
| ENSMUSG00000027261| | Hao1 | Hydroxyacid oxidase 1 [Mus musculus] | mRNA | 2.43 |
| ENSMUSG00000046840 | Hnf4aos | Hepatic nuclear factor 4 alpha, opposite strand | ncRNA | 2.19 |
| ENSMUSG00000048482| | Bdnf | brain derived neurotrophic factor | mRNA | 1.26 |
| ENSMUSG00000085667| | Gm12992 | predicted gene 12992 | mRNA | 2.04 |
| ENSMUSG00000020901| | Pik3r5 | phosphoinositide-3-kinase regulatory subunit 5 | mRNA | 0.41 |
| ENSMUSG00000023809| | Rps6ka2 | ribosomal protein S6 kinase, polypeptide 2 | mRNA | 0.47 |
| ENSMUSG00000004933| | Matk | megakaryocyte-associated tyrosine kinase | mRNA | 0.08 |
| TNF signaling pathway | ||||
| ENSMUSG00000085667| | Gm12992 | Predicted gene 12992 | ncRNA | 2.64 |
| ENSMUSG00000021367| | Edn1 | Endothelin 1 | mRNA | 2.16 |
| ENSMUSG00000035385| | Ccl2 | Chemokine (C-C motif) ligand 2 | mRNA | 2.41 |
| ENSMUSG00000034394| | Lif | Leukemia inhibitory factor | mRNA | 3.06 |
| ENSMUSG00000029380| | Cxcl1 | Chemokine (C-X-C motif) ligand 1 | mRNA | 0.20 |
| ENSMUSG00000053113| | Socs3 | Suppressor of cytokine signaling 3 | mRNA | 0.37 |
| ENSMUSG00000021250| | Fos | FBJ osteosarcoma oncogene | mRNA | 0.23 |
| ENSMUSG00000027398| | Il1b | Interleukin 1 beta | mRNA | 0.31 |
| ENSMUSG00000020901| | Pik3r5 | Phosphoinositide-3-kinase regulatory subunit 5 | mRNA | 0.41 |
| ENSMUSG00000058427| | Cxcl2 | Chemokine (C-X-C motif) ligand 2 | mRNA | 0.04 |
| ENSMUSG00000032487| | Ptgs2 | Prostaglandin-endoperoxide synthase 2 | mRNA | 0.05 |
| Ubiquitin mediated proteolysis | ||||
| ENSMUSG00000085995| | Gm2788 | Predicted gene 2788 | 2.01 | |
| ENSMUSG00000105987| | AI506816 | Expressed sequence AI506816 | ncRNA | 2.08 |
| ENSMUSG00000006398| | Cdc20 | Cell division cycle 20 | mRNA | 2.53 |
| ENSMUSG00000053113| | Socs3 | Suppressor of cytokine signaling 3 | mRNA | 0.37 |
| ENSMUSG00000052981| | Ube2ql1 | Ubiquitin-conjugating enzyme E2Q family-like 1 | mRNA | 0.08 |
| ENSMUSG00000111626| | APC10, DOC1 | Anaphase-promoting complex subunit 10 | mRNA | 0.20 |
Figure 5qRT-PCR validations of differentially expressed RNAs.